Does Time-to-Chemotherapy after Primary Complete Macroscopic Cytoreductive Surgery Influence Prognosis for Patients with Epithelial Ovarian Cancer? A Study of the FRANCOGYN Group

Grégoire Rocher (1, 2, 3) , Thomas Gaillard (1, 3) , Catherine Uzan (1, 2, 4, 3) , Pierre Collinet (5) , Pierre-Adrien Bolze (6) , Marcos Ballester (7) , Sofiane Bendifallah (8, 3) , Lobna Ouldamer (9) , Cyril Touboul (8, 3) , Cyrille Huchon (10) , Vincent Lavoue (11) , Yohann Dabi (12) , Cherif Akladios (13) , Charles Coutant (14) , Emilie Raimond (15) , Alexandre Bricou (16) , Geoffroy Canlorbe (1, 2, 4, 3) , Henri Azaïs (1, 3)

1 CHU Pitié-Salpêtrière [AP-HP]
2 CRSA - Centre de Recherche Saint-Antoine
3 SU FM - Sorbonne Université - Faculté de Médecine
4 IUC - Institut Universitaire de Cancérologie [Sorbonne Université]
5 Hôpital Jeanne de Flandres
6 CHLS - Centre Hospitalier Lyon Sud [CHU - HCL]
7 Groupe Hospitalier Diaconesses Croix Saint-Simon
8 CHU Tenon [AP-HP]
9 Hôpital Bretonneau
10 Service de gynécologie et obstétrique [CHI Poissy-Saint Germain]
11 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou]
12 CHIC - Centre Hospitalier Intercommunal de Créteil
13 CHU Strasbourg - Centre Hospitalier Universitaire [Strasbourg]
14 UNICANCER/CRLCC-CGFL - Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon]
15 Hôpital universitaire Robert Debré [Reims]
16 Hôpital Jean Verdier [AP-HP]

To determine if the time-to-chemotherapy (TTC) after primary macroscopic complete cytoreductive surgery (CRS) influences recurrence-free survival (RFS) and overall survival (OS) in patients with epithelial ovarian cancer (EOC). We conducted an observational multicenter retrospective cohort analysis of women with EOC treated from September 2006 to November 2016 in nine institutions in France (FRANCOGYN research group) with maintained EOC databases. We included women with EOC (all FIGO stages) who underwent primary complete macroscopic CRS prior to platinum-based adjuvant chemotherapy. Two hundred thirty-three patients were included: 73 (31.3%) in the early-stage group (ESG) (FIGO I-II), and 160 (68.7%) in the advanced-stage group (ASG) (FIGO III-IV). Median TTC was 43 days (36–56). The median OS was 77.2 months (65.9–106.6). OS was lower in the ASG when TTC exceeded 8 weeks (70.5 vs. 59.3 months, p = 0.04). No impact on OS was found when TTC was below or above 6 weeks (78.5 and 66.8 months, respectively, p = 0.25). In the whole population, TTC had no impact on RFS or OS. None of the factors studied were associated with an increase in TTC. Chemotherapy should be initiated as soon as possible after CRS. A TTC greater than 8 weeks is associated with poorer OS in patients with advanced stage EOC.

Mots clés: epithelial ovarian cancer; chemotherapy; prognosis

Domaines: Sciences du Vivant [q-bio]

Grégoire Rocher, Thomas Gaillard, Catherine Uzan, Pierre Collinet, Pierre-Adrien Bolze, et al.. Does Time-to-Chemotherapy after Primary Complete Macroscopic Cytoreductive Surgery Influence Prognosis for Patients with Epithelial Ovarian Cancer? A Study of the FRANCOGYN Group. Journal of Clinical Medicine, 2021, 10 (5), pp.1058. ⟨10.3390/jcm10051058⟩. ⟨hal-03163298⟩